Annovis Bio Inc (ANVS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Annovis Bio Inc   (NYSE: ANVS)


Annovis Bio Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Annovis Bio Inc's ROI in the second quarter of 2026?
Annovis Bio Inc recorded a cumulative net loss of $-50 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -328.99%.

Within the Healthcare sector 777 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 4301, from total ROI ranking in the first quarter of 2026 at 4832.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -3.9 % 58.83 % 329.01 % 364.11 % 338.66 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 16 11 18 15 20
Return On Investment (TTM) -328.99 % -251.77 % -145.33 % -141.73 % -193.17 %
ANVS's Overall Ranking # 4301 # 4832 # 4276 # 4396 # 4522
Seq. Investment Change TTM -7.39 % -18.13 % 13.08 % 12.08 % 53.07 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -50 -41 -29 -25 -30

ANVS Company Profile >> Back to ANVS Roi Comparisons >> See Annual ANVS Return On Investment



Return On Investment ANVS's Ranking
Within: No.
Industry # 372
Sector # 778
Overall # 4301

Return On Investment Statistics
High Average Low
-16.52 %
-227.98 %
-1041.6 %
(Mar 31 2020)   (Jun 30 2024)



  News about Annovis Bio Inc Return on Investment ROI

Annovis Bio Advances Alzheimer’s Research with FDA Endorsement and Upcoming Presentations at CTAD 2024

October 22, 2024

In the ongoing race to unlock effective treatments for neurodegenerative disorders, particularly Alzheimer’s disease (AD), Annovis Bio Inc. (NYSE: ANVS) is making notable strides that reflect the increased investment in and urgency surrounding Alzheimer’s research. With the approaching Clinical Trials on Alzheimer s Disease (CTAD) conference set to take place from October 29 to November 1, 2024, in Madrid, Spain, Annovis is poised to showcase its advancements related to its investigational drug, buntanetap.The company recently announced its plan to present two scientific posters detailing fresh findings that highlight the potential of buntanetap as an innovative therapeutic option for early-stage AD patients. Annovis’s research comes at a crucial moment when the need for viable Alzheimer’s treatments is more pronounced than ever, given the increasing prevalence of the disease worldwide. Currently, AD affects millions of individuals and poses a significant burden on caregivers and healthcare systems.

Annovis Bio Adds Four Executives to Leadership Team; Aims to Overcome Financial Challenges and Boost ROI.

July 9, 2024

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
Annovis Bio Inc., a late-stage clinical drug platform company specializing in transformative therapies for neurodegenerative disorders such as Alzheimer s Disease (AD) and Parkinson s Disease (PD), is pleased to announce the addition of four accomplished professionals to its executive team. Despite recording a cumulative net loss of $48 million during the 12 months ending in the first quarter of 2024, resulting in a negative return on investment (ROI) of -524.18%, the company remains optimistic about its future prospects. However, it is worth noting that within the Healthcare sector, there are 577 other companies that have a higher return on investment, indicating room for improvement. Furthermore, the company s total ranking in terms of ROI has deteriorated from 3307 in the fourth quarter of 2023 to 3330 currently





Financial Statements
Annovis Bio Inc's II. Quarter Investments $ 16 Millions ANVS's Balance sheet
Annovis Bio Inc's II. Quarter Income $ -15 Millions Quarterly ANVS's Income Statement
ANVS's Income by Division See ANVS's Income by Division


ANVS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 17 9 6 28 44
Y / Y Investment Growth 81.05 % 56.98 % -79.07 % -36.34 % 490.04 %
Net Income in Millions -29 -25 -56 -25 -14
Y / Y Net Income Growth - - - - -
Annual Return On Investment -171.23 % -264.2 % -947.93 % -89.43 % -32.56 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANVS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANVS's Competitors
Subscribers only: Roi for Annovis Bio Inc's Suppliers
Subscribers only: Return On Investment for ANVS's Customers

Other Ratios
ANVS's Roa ANVS's Inventory Turnover Ratio ANVS's Growth Rates ANVS's Dividend Statistics
ANVS's Profitability Ratios ANVS's Asset Turnover Ratio ANVS's Dividend Growth
ANVS's Roe ANVS's Valuation Ratios ANVS's Financial Strength Ratios ANVS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:38:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.